Dr. Muss Discusses Evaluating Cardiac Toxicity in Patients With Breast Cancer

Hyman B. Muss, MD
Published Online: Monday, May 12, 2014
Hyman B. Muss, MD, professor of oncology, University of North Carolina, director, Geriatric Oncology, Lineberger Comprehensive Cancer Center, discusses evaluating cardiac toxicity in patients with breast cancer.

Oncologists are now used to doing echocardiograms, which do not require any isotopes and yield rich results, or multigated acquisition (MUGA) scans, which yield results as one simple number.

Muss hypothesizes that in 5-10 years, the best way to monitor cardiac toxicity may be with an MRI of the heart and that those who are researching heart MRI are seeing incredible results.

Online CME Activities
Free CME from PER
Cardiology Review/CME Reviews: Volume 31, Number 2
Community Practice Connections: 19th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and Myeloma
Addressing Disparities in Care Specific to Patients With Lung Cancer: Health Literacy
Addressing Disparities in Care Specific to Patients With Lung Cancer: Patient Cases
More Reading
$auto_registration$